Gliptins.
Grouzmann
Eric
E
Buclin
Thierry
T
Biollaz
Jérôme
J
D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives*; D000243:Adenosine Deaminase / Q000097:blood / Q000502:physiology*; D058892:Adenosine Deaminase Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D018819:Dipeptidyl Peptidase 4 / Q000097:blood / Q000502:physiology*; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology*; D006801:Humans; D009478:Neuropeptide Y / Q000187:drug effects; D009570:Nitriles; D011759:Pyrrolidines; D000077597:Vildagliptin
D058892:Adenosine Deaminase Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D009478:Neuropeptide Y; D009570:Nitriles; D011759:Pyrrolidines; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000243:Adenosine Deaminase; D000077597:Vildagliptin; D000218:Adamantane